
Tuberculosis: Extensively drug-resistant tuberculosis (XDR-TB)
2024年5月23日 · XDR-TB, an abbreviation for extensively drug-resistant tuberculosis (TB), is a form of TB that is caused by a strain of M. tuberculosis complex that is resistant to rifampicin (and may also be resistant to isoniazid), and that is also resistant to at least one fluoroquinolone (levofloxacin or moxifloxacin) and to at least one other Group A drug ...
Tuberculosis: Multidrug-resistant (MDR-TB) or rifampicin-resistant TB …
2024年5月20日 · Multidrug-resistant TB (MDR-TB) is a form of TB disease caused by a strain of M. tuberculosis complex that is resistant to rifampicin and isoniazid. Globally, an estimated 410 000 people (95% UI: 370 000–450 000) developed multidrug- or rifampicin-resistant tuberculosis (MDR/RR-TB) in 2022.
About Drug-Resistant Tuberculosis Disease | Tuberculosis (TB)
2023年12月21日 · Multidrug-resistant TB disease (MDR TB) is caused by germs that are resistant to two or more of the main TB medicines: isoniazid and rifampin. Two more serious forms of MDR TB are called pre-extensively drug-resistant TB (pre-XDR TB) …
Clinical Overview of Drug-Resistant Tuberculosis Disease
2025年1月6日 · Extensively drug-resistant TB (XDR TB) is a rare type of MDR TB caused by TB bacteria that are resistant to: Isoniazid and rifampin, a fluoroquinolone, and a second-line injectable (amikacin, capreomycin, and kanamycin) or
2.4 Drug-resistant TB treatment - World Health Organization (WHO)
The short 6-month regimen is prioritized for use and is recommended for people aged 14 years and older who have MDR/RR-TB or pre-XDR-TB. By the end of 2022, 40 countries had started to use the BPaLM/BPaL regimens for the treatment of MDR/RR-TB or pre-XDR-TB (Fig. 2.4.9). In 2022, 1745 people with MDR/RR-TB were reported to have been started on ...
5 Treatment strategies for MDR-TB and XDR-TB - National …
This chapter provides guidance on the strategies for the treatment of multidrug- and extensively drug-resistant TB (M/XDR-TB), with emphasis on regimen design. The treatment of mono- and poly-drug-resistant TB is addressed in Chapter 6.
Multidrug-resistant tuberculosis - Nature Reviews Disease Primers
2024年3月24日 · Pre-extensively drug-resistant TB (pre-XDR-TB) refers to MDR/RR-TB that is also resistant to a fluoroquinolone, and extensively drug-resistant TB (XDR-TB)...
Treatment of Drug-Resistant and Drug-Susceptible TB
2024年12月30日 · Before 2019, global treatment success rates for MDR-TB ranged from 50% to 88% (1, 17), often accompanied by significant adverse events. However, the Nix-TB study demonstrated a 90% treatment success rate for treatment of extensively drug-resistant (XDR) or MDR-TB using a regimen of bedaquiline, pretomanid, and linezolid (BPaL) over a 6-month ...
The Difference Between Multidrug-Resistant TB MDR-TB and …
Multidrug resistance (MDR) is when both isoniazid and rifampicin fail to work against TB infection. Extensively drug-resistant TB (XDR-TB) is a form of TB that is resistant to at least four of the core anti-TB drugs. XDR-TB involves resistance to the two most powerful anti-TB drugs, namely isoniazid and rifampicin.
【重磅】世卫组织公布新的Pre-XDR-TB和XDR-TB定义_百度文库
Pre-XDR-TB:由符合MDR/RR-TB定义、同时对任意氟喹诺酮类药物耐药的结核分枝杆菌(M.tuberculosis)菌株引起的结核病; -在WHO推荐的短程和长程治疗方案间做出一个重大的抉择(包括目前推荐在实施性研究情境下推荐的治疗方案);或
- 某些结果已被删除